Alberta Investment Management Corp lifted its holdings in shares of The Clorox Company (NYSE:CLX – Free Report) by 526.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 25,700 shares of the company’s stock after purchasing an additional 21,600 shares during the period. Alberta Investment Management Corp’s holdings in Clorox were worth $4,174,000 at the end of the most recent reporting period.
Several other large investors have also added to or reduced their stakes in the business. Brooklyn Investment Group increased its stake in Clorox by 163.8% in the fourth quarter. Brooklyn Investment Group now owns 153 shares of the company’s stock valued at $25,000 after purchasing an additional 95 shares in the last quarter. Prospera Private Wealth LLC bought a new position in shares of Clorox during the 3rd quarter worth about $27,000. Continuum Advisory LLC grew its stake in shares of Clorox by 300.0% in the 3rd quarter. Continuum Advisory LLC now owns 184 shares of the company’s stock valued at $30,000 after buying an additional 138 shares during the period. Asset Planning Inc bought a new stake in Clorox in the 4th quarter valued at about $32,000. Finally, Catalyst Capital Advisors LLC acquired a new position in Clorox during the 3rd quarter worth approximately $54,000. Institutional investors and hedge funds own 78.53% of the company’s stock.
Clorox Trading Up 1.2 %
NYSE:CLX opened at $152.93 on Friday. The Clorox Company has a 52 week low of $127.60 and a 52 week high of $171.37. The firm has a 50-day moving average price of $158.11 and a two-hundred day moving average price of $159.68. The firm has a market cap of $18.84 billion, a price-to-earnings ratio of 41.78, a price-to-earnings-growth ratio of 2.54 and a beta of 0.42. The company has a debt-to-equity ratio of 20.52, a quick ratio of 0.60 and a current ratio of 0.94.
Analyst Upgrades and Downgrades
Several research analysts have issued reports on CLX shares. DA Davidson reduced their price objective on Clorox from $171.00 to $169.00 and set a “neutral” rating for the company in a research note on Wednesday, February 5th. StockNews.com cut Clorox from a “buy” rating to a “hold” rating in a report on Sunday, January 5th. Evercore ISI boosted their price target on shares of Clorox from $145.00 to $155.00 in a research note on Tuesday, February 4th. JPMorgan Chase & Co. upped their price objective on shares of Clorox from $171.00 to $173.00 and gave the stock a “neutral” rating in a report on Tuesday, February 4th. Finally, Wells Fargo & Company lifted their price objective on shares of Clorox from $157.00 to $161.00 and gave the company an “equal weight” rating in a report on Tuesday, February 4th. Four research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and one has issued a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $158.21.
View Our Latest Report on Clorox
Clorox Profile
The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.
See Also
- Five stocks we like better than Clorox
- How to Invest in the Best Canadian StocksĀ
- Ray Dalio’s Bridgewater Loaded Up on These Stocks in Q4 2024
- How to Plot Fibonacci Price Inflection Levels
- Walmart Faces Tariff Headwinds, Consumer Trends Remain Positive
- Top Biotech Stocks: Exploring Innovation Opportunities
- Tesla: 2 Reasons to Buy, 1 Reason to Run
Want to see what other hedge funds are holding CLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for The Clorox Company (NYSE:CLX – Free Report).
Receive News & Ratings for Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox and related companies with MarketBeat.com's FREE daily email newsletter.